FDA 483 - Lilly del Caribe, Inc. - February 17, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Lilly del Caribe, Inc. in Carolina, PR, revealed two significant observations regarding quality unit failures. The firm failed to thoroughly investigate a microbial contamination discrepancy in a drug substance batch, leading to insufficient corrective actions. Additionally, the quality unit did not properly review and approve batch records and quality-related documents, resulting in manufacturing issues due to unapproved and untrailed procedural changes.
ID · 0077c94c-6068-4f48-9c88-b92150dd9273